(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 16.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Catalyst Pharmaceuticals's revenue in 2024 is $398,204,000.On average, 5 Wall Street analysts forecast CPRX's revenue for 2024 to be $54,287,816,635, with the lowest CPRX revenue forecast at $53,940,120,024, and the highest CPRX revenue forecast at $54,877,132,925. On average, 5 Wall Street analysts forecast CPRX's revenue for 2025 to be $63,756,479,329, with the lowest CPRX revenue forecast at $61,514,012,983, and the highest CPRX revenue forecast at $68,337,116,988.
In 2026, CPRX is forecast to generate $74,074,700,388 in revenue, with the lowest revenue forecast at $67,351,780,152 and the highest revenue forecast at $81,738,169,423.